No Data
No Data
Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS), Incyte (INCY) and Prenetics Group (PRE)
Incyte Gets FDA Orphan Designation for Treatment of Nodal Marginal Zone Lymphoma
S&P and Nasdaq on Track for Third Record Close This Week | Live Stock
Incyte Gains Amid Takeover Speculation
Fresh Closing Highs from S&P 500 and Nasdaq | Wall Street Today
Incyte Insider Sold Shares Worth $455,544, According to a Recent SEC Filing
No Data